For HNSCC, including OSCC, it is particularly effective in recurrent or metastatic disease, especially in PD-L1–expressing tumors [121,169], and is also approved for advanced urothelial carcinoma [170,171]. Here, CD274 is linked to head and neck squamous cell carcinoma.